Gentium | Evaluate

Defitelio highlights a regulatory fault line

Development-stage M&A premiums reward very patient investors

January 07, 2014

Biotech bull run leaves few big cap drug stocks down in 2013

December 20, 2013

Jazz plays the M&A song again

April 23, 2013

Orphan diseases’ appeal lies in return on investment

December 24, 2012

Midcap players ask Europe to bring it on in 2013

January 03, 2012

Regulatory and clinical developments over the Christmas period

January 09, 2009

Emergent tops slim list of stock market winners for 2008

October 30, 2008

Big Pharma hunting for bargains have plenty of choice

August 07, 2008

Companies on the way to being 2008's winners and losers - European focus